Elanco Animal Health (NYSE:ELAN) Board of Directors Approves Share Buyback Program

Elanco Animal Health logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Elanco’s board authorized a $600 million share repurchase program, allowing the company to buy back up to 4.5% of its shares through open-market purchases.
  • Analysts have a consensus “Moderate Buy” rating and an average price target of $30.36; nine rate the stock Buy, two Hold, and one Sell.
  • For its latest reported quarter, Elanco posted EPS of $0.27, beating the $0.20 consensus, while revenue rose 11.3% year over year to $1.26 billion.
  • Interested in Elanco Animal Health? Here are five stocks we like better.

Elanco Animal Health (NYSE:ELAN - Get Free Report) announced that its Board of Directors has initiated a stock buyback plan on Thursday, November 19th, RTT News reports. The company plans to repurchase $600 million in shares. This repurchase authorization permits the company to repurchase up to 4.5% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

ELAN has been the subject of several research analyst reports. UBS Group lifted their target price on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Jefferies Financial Group downgraded shares of Elanco Animal Health from a "buy" rating to a "hold" rating and cut their price objective for the company from $31.00 to $24.00 in a report on Tuesday, October 20th. Barclays increased their target price on shares of Elanco Animal Health from $30.00 to $32.00 and gave the stock an "overweight" rating in a research report on Thursday. The Goldman Sachs Group assumed coverage on Elanco Animal Health in a research report on Friday, October 16th. They set a "buy" rating and a $32.00 price target on the stock. Finally, Weiss Ratings raised shares of Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a report on Friday, September 4th. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $30.36.

View Our Latest Stock Analysis on Elanco Animal Health

Elanco Animal Health Stock Down 1.4%

Elanco Animal Health stock traded down $0.38 during mid-day trading on Thursday, reaching $26.32. The stock had a trading volume of 7,049,986 shares, compared to its average volume of 5,428,598. The firm has a market capitalization of $13.15 billion, a PE ratio of -87.72, a price-to-earnings-growth ratio of 2.26 and a beta of 1.73. Elanco Animal Health has a fifty-two week low of $19.40 and a fifty-two week high of $27.98. The stock's 50-day simple moving average is $23.59 and its 200-day simple moving average is $23.92. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.07 and a current ratio of 2.09.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings results on Friday, November 6th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.07. The business had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.21 billion. Elanco Animal Health had a negative net margin of 2.86% and a positive return on equity of 8.80%. Elanco Animal Health's revenue was up 11.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.19 EPS. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. On average, sell-side analysts forecast that Elanco Animal Health will post 1.18 EPS for the current fiscal year.

Insider Activity

In other news, insider Timothy Bettington sold 4,350 shares of the business's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $23.00, for a total transaction of $100,050.00. Following the completion of the sale, the insider directly owned 138,911 shares of the company's stock, valued at $3,194,953. The trade was a 3.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.14% of the stock is owned by corporate insiders.

Elanco Animal Health Company Profile

(Get Free Report)

Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health. For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Elanco Animal Health Right Now?

Before you consider Elanco Animal Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elanco Animal Health wasn't on the list.

While Elanco Animal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines